Kynexis
Kynexis is developing an asset with the ambition to treat Cognitive Impairment Associated in patients with Scizophrenia (CIAS).
A significant challenge in improving the lives of people who have schizophrenia has been developing a treatment for CIAS, which is a major cause of disability for over 24 million affected people worldwide. The dysregulation of kynurenic acid is hypothesized to cause cognitive impairment in people with schizophrenia, and the company takes a biomarker-based approach to identify patients most likely to benefit from a potential new therapy.
For more information, please contact:
Phone +45 2481 6967